Provocative Questions
The
NCI's Provocative Questions (PQ) Initiative has assembled a list of 12 important, but non-obvious or understudied, questions based on input from the NCI's extramural research community to stimulate use of laboratory, clinical and population sciences in especially effective and imaginative ways to answer the questions. The current list of 12 PQs is updated from previous PQ Funding Opportunity Announcements (FOAs).
Receipt dates are Jun 28, 2017; Oct 30, 2017; Jun 28, 2018; Oct 30, 2018.
Applications in response to a selected PQ should build on specific advances in our understanding of cancer and cancer control, address broad issues in biology of cancer that have proven difficult to resolve, take into consideration the likelihood of progress in the foreseeable future (e.g. 5 to 10 years), and address ways to overcome obstacles to achieving long-term goals.
Current RFAs
|
CFAR Retreat
You are invited to attend the
Seventh Annual Internal Scientific Retreat for CWRU/UH Center for AIDS Research (CFAR)
. This one-day meeting is designed to highlight the
scientific studies undertaken by CFAR members. The meeting will be
organized by Working Group, and each session will conclude with a
panel discussion chaired by the appropriate leader of the Working
Group. We will also include a session on activity at the national level
among the CFAR Directors.
To register, please email Brinn Omabegho, Department Manager, CFAR Coordinator, at
[email protected] by Thurs, Mar 23.
|
Case CCC Clinical Research Retreat
Apr 17, 2017 | Wolstein Research Building
The Case Comprehensive Cancer Center Clinical Research Retreat will take place Monday, Apr 17 from 5-7p in the Wolstein Research Building on CWRU campus. The agenda will focus on "How do I get an investigator-initiated trial approved and funded." Attendees will be eligible to receive 1.5 CME Category 2 hours.
Pre-registration is required
.
|
AACI Clinical Research Initiative Meeting
Jul 12-13, 2017 | Loews Chicago O'Hare Hotel
Last year's CRI annual meeting attracted 302 attendees discussing a variety of issues related to the conduct of cancer clinical trials at academic cancer centers. The goal of the AACI CRI is to improve clinical trials management at cancer centers. To help achieve this goal, the CRI annual meeting provides opportunities for clinical trials office administrative and medical directors and staff to share best practices - through peer-to-peer networking, collaboration and ongoing communication - that can lead to the development of more effective treatments for patients.
The
deadline to submit abstracts for consideration for presentation at the meeting is Tuesday, May 9, at 5p PST.
|
Mesenchymal Stem Cell Conference 2017
Aug 14-16, 2017 | Marriott Key Center
The National Center for Regenerative Medicine announces the
Mesenchymal Stem Cell Conference (MSC) 2017. This conference will serve as a forum to exchange and discuss cutting-edge breakthroughs in translational stem cell therapy and regenerative medicine.
Highlights
- Invited lectures by domestic & international thought-leaders
- Pre-conference workshop for young investigators
- Stem Cell Tourism panel discussion
- Short talks (selected from abstracts)
- Poster session & networking reception
- Innovative Start-up award
- Best poster awards
Call for Abstracts
The MSC 2017 Conference Directors invite you to
submit abstracts of original investigation for consideration for best poster awards, short talks, and poster presentations. Individuals must be registered for the meeting to present a short talk or poster. There is no limit to the number of abstracts an individual can submit.
Submission Deadline: Jun 2, 2017
|
International Cancer Education Conference
Sep 13-15, 2017 | Westin Cleveland Downtown
 The International Cancer Education Conference is the only meeting in North America totally dedicated to cancer education - ranging from medical professionals to patients and community education. We invite you to submit an abstract and attend this meeting of national and international specialists in cancer education, survivorship and palliative care focused on advocacy, scientific investigation, program and curriculum development, skill training, and evaluation. National leaders will be presenting special programs on grant writing (National Cancer Institute), cancer and the elderly (Cancer and Aging Research Group), surgical oncology (American College of Surgeons), plus dedicated mentoring opportunities will be available to present to content experts. The deadline for oral and poster presentations is April 3, 2017.
|
GvHD National Symposium 2017
Oct 13, 2017 | Columbus, OH
 The
GvHD National Symposium focuses on cutting edge research and new treatments, and consists of two tracks: one designed for physicians and other health care professionals, and one for bone marrow transplant (BMT) survivors, their families and caregivers. The Meredith A. Cowden Foundation in collaboration with the Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, and Cleveland Clinic Taussig Cancer Institute, created this annual event to raise awareness about GvHD, to promote research to further our understanding of its cause, and to review cutting edge approaches to prevention and treatment. Registration will open soon.
|
| CASE CCC IN THE NEWS |
Popular Prostate Cancer Therapy Is Short, Intense and Unproven
NY Times - Mar 20, 2017
After learning he had early stage prostate cancer, Paul Kolnik knew he wanted that cancer destroyed immediately and with as little disruption as possible to his busy life as the New York City Ballet's photographer...The National Cancer Institute has just agreed to fund a clinical trial that researchers hope will settle which treatment is better. It will randomly assign 538 men to have either a short course of five intense radiation sessions over two weeks or 28 treatments over five and a half weeks, comparing outcomes for quality of life as well as disease-free survival.
But it will be at least eight years before the answers are in. In the meantime, men and their doctors are left with uncertainty. "
Ideally, we want to show five treatments is better," said Dr. Rodney J. Ellis, a radiation oncologist at Case Comprehensive Cancer Center and University Hospitals Cleveland Medical Center and the principal investigator for the trial.
|
Colon Cancer Cases Increasing in Younger Patients
ideastream - Mar 16, 2017
Colon cancer often gets tagged as an "older person's" disease. But there is an uptick in the occurence of colon cancer in young people, according to a new American Cancer Society study, and often the disease is more advanced than it is when older patients are diagnosed.
Guests:
Dr. Alok Khorana, MD, Medical Oncologist, Case Comprehensive Cancer Center and Cleveland Clinic;
Deanna Pisano, Diagnosed with Colon Cancer at age 25;
Rebecca Siegel, Epidemiologist, Lead Study Author, American Cancer Society.
|
ideastream - Mar 14, 2017
Gerald Lyman is speaking with his oncologist, Dr. Dale Shepard, during his cancer treatment that happens every 3 weeks at the Cleveland Clinic. Back in 2013, Lyman was diagnosed with stage 4 bladder cancer, with little chance of survival. When chemotherapy and experimental drugs didn't work, he opted to try a clinical trial for a medicine designed to harness his immune system to fight the cancer - a new category of treatment known as immunotherapy. According to Dr. Shepard, also of the Case Comprehensive Cancer Center, Lyman was one of the first patients to try a new drug to treat the tumor that engulfed his bladder. And after about a month of treatment, he presented a big surprise.
|
The Plain Dealer - Mar 10, 2017
About 150 folks are looking a little shiny on top after having their heads shaved Friday as part of the
St. Baldrick's Foundation
cancer research drive Friday at Rainbow Babies & Children's Hospital...Lauren Huang shaves the head of her father Dr. Alex Huang, from Case Comprehensive Cancer Center, University Hospitals, at the annual St. Baldrick's Foundation fund raising event for cancer research held at Rainbow Babies & Children's Hospital, in Cleveland, Ohio on March 10, 2017. Dr. Huang's whole cancer research department takes part in the annual head shaving festivities every year...Luke Baum, from Shaker Heights, and Dr. John Letterio, Case Comprehensive Cancer Center, University Hospitals, pose for a photograph right after they got their heads shaved at the annual St. Baldrick's Foundation fund raising event...
|
OncLive - Mar 10, 2017
Eric Klein, MD, Case Comprehensive Cancer Center, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses gene mutations in patients with prostate cancer.
|
ASCO Post - Mar 10, 2017
The new Cleveland Clinic Taussig Cancer Center began welcoming patients on March 6, 2017. The 377,000 square-foot facility houses all outpatient cancer treatment services in one location, with the center's team of medical and radiation oncologists, surgeons, nurses, genetic counselors, social workers, and other health-care providers all working together in one shared space to improve patient outcomes..."As one of the nation's most progressive cancer centers, the new Taussig Cancer Center will provide a seamless, personalized experience," said Brian J. Bolwell, MD, FACP, Chairman of the Cleveland Clinic Taussig Cancer Institute, and Associate Director for the Taussig Cancer Institute, Case Comprehensive Cancer Center.
|
ideastream - Mar 9, 2017
According to the American Cancer Society, lung cancer is the leading cause of cancer death in the country. In fact, it kills more people than colon, prostate, and breast cancers combined. In Northeast Ohio, lung cancer hits particularly hard and experts say that has a lot to do with the high rate of smoking. In Cleveland the rate of smoking is more than twice the rate of the national average, and the death rate from lung cancer is two-thirds higher.
As part of the Be Well series Navigating Cancer, Managing Producer of Health Kay Colby sat down with Dr. Stan Gerson, director of the
Case Comprehensive Cancer Center
, to find out about local efforts to put a dent in the alarming statistics related to smoking and lung cancer deaths.
|
New Cancer Treatments Bringing Hope of Longer Survival for Some Kinds of Cancer
ideastream - Mar 7, 2017
Ten years ago lung cancer was considered one disease and all patients were treated with either surgery, chemo or radiation, but now there are targeted treatments for specific kinds of lung cancers, said her oncologist
,
Dr. Afshin Dowlati, of Case Comprehensive Cancer Center and University Hospitals.
These targeted therapy medications are for people with a specific mutation in their cancer which the drugs can attack.
|
Limited Submission Reminder: NIH: High-End Instrumentation Grant (HEI) Program (S10)
CWRU Internal Submission Deadline: Mar 24
External Deadline: May 31
Central review of internal LOIs will be limited to ensuring that the applications do not duplicate other equipment requested. Applicants must work with their school or college dean to ensure that all financial aspects of the application are approved before submission. Each school or college dean has the right to deny any application submission that does not have an appropriate financial plan in place. Applicants are strongly encouraged to begin discussions with their Associate Dean for Research before submitting an internal LOI.
The purpose of this funding opportunity is to continue the High-End Instrumentation (HEI) Grant Program administered by ORIP. The objective of the Program is to make available to institutions expensive research instruments that can only be justified on a shared-use basis and that are needed for NIH-supported projects in basic, translational or clinical areas of biomedical/behavioral research. The HEI Program provides funds to purchase or upgrade a single item of expensive, specialized, commercially available instrument or an integrated instrumentation system. An integrated instrumentation system is one in which the components, when used in conjunction with one another, perform a function that no single component could provide. The components must be dedicated to the system and not used independently.
|
Opportunities for Pilot Projects in Genomics
Deadline: Apr 21, 2017
The Case Comprehensive Cancer Center is providing
seed funding for the initiation of novel projects that focus on genomic analyses of tissue/blood samples from patients seen at University Hospitals of Cleveland. Projects must be aligned with at least one of the seven Research Programs (GI Cancer Genetics, Molecular Oncology, GU Malignancies, Hematopoietic and Immune Cancer Biology, Developmental Therapeutics, Cancer Imaging, or Cancer Prevention, Control, & Population Research) or the Brain Tumor, Breast Cancer, or AYA research initiatives within the Center. Highly innovative and impactful proposals are sought that will generate key data for larger, nationally competitive grants that interface with the Strategic Plan of the aligned program(s). Collaborative, multi-investigator projects are particularly encouraged. Analysis of samples obtained from patients in clinical trials, high risk families, or underserved populations are particularly encouraged. Use of genomics tools is required with preference for sequencing and analytics studies preferred through the genomics shared resource or through UHTL. IRB review may be pending at the time of submission.
Award Description:
- Funding for research teams with projects that are aligned with one of the Cancer Center Research Programs or Initiatives.
- Up to 5 research projects will be funded. Total funds committed to this RFA are $250,000.
- Each research project can request a budget of up to $50,000 for one year.
- Research projects should be completed within 1 year.
|
Pilot Projects in Cancer Disparities Research
Deadline: Apr 7, 2017
A major goal of the Office of Cancer Disparities Research and the Case Comprehensive Cancer Center (Case CCC) at Case Western Reserve University is to reduce and eliminate social and racial/ethnic disparities in cancer outcomes. Efforts toward overcoming cancer disparities have great potential to achieve cancer health equity. However, research advances in cancer prevention, detection, screening, diagnosis, treatment, and survivorship have not affected all segments of the U.S. population equally, particularly those characterized by race/ethnicity, socioeconomic status, health insurance status, and/or geographic location. Many of these disparities are also observed within the Case CCC catchment area.
The main goal of this RFA is to stimulate novel research designed to (1) improve understanding of the causes of cancer disparities and (2) develop and test interventions for reducing and ultimately eliminating them. Transdisciplinary, interprogrammatic, and translational approaches are especially encouraged, as are new investigator proposals.
Funding Criteria:
- Up to 3 pilots of $50,000 will be awarded.
- Strong collaborative investigative teams of Case Comprehensive Cancer Center members that clearly demonstrate programmatic alignment.
- Highly innovative and impactful projects.
- All materials to complete the project should be in-hand or readily available. For example, tissue-based research will require an approved IRB protocol and patient cohort studies must have already recruited the cohort. Collection of new patient cohorts is not responsive to this RFA.
- Projects must have a high likelihood of subsequent national-level funding.
- While investigators can be collaborators on multiple applications, only one application will be accepted per lead PI.
- All funds for core facilities must use Case Comprehensive Cancer Center cores, when available, rather than cores at institutions outside Cleveland.
|
Alex's Lemonade Stand Foundation
Deadline: May 22
The purpose of the
Reach Grant is to advance Alex's Lemonade Stand Foundation's mission to find cures and better treatments for childhood cancers by providing support to move hypothesis-driven research into the clinic. Significant barriers exist that impede the translation of innovative and important ideas to the clinic. The Reach Grant seeks to remove one of these barriers by providing support for important preclinical projects that are necessary to move a study from the pre-clinical arena into a clinical trial. Thus, the goal of this award is to support selected late translational studies. Preference will be given to those research projects which, if funded, will likely result in the initiation of a clinical trial two to three years from the start of the project.
Applicant Eligibility Criteria
- Primary applicants may be Assistant, Associate or Professor level investigators who demonstrate a track record of discovery, investigation and external funding.
- Applicants must be MD, DO, PhD or MD/PhD
- Applicants must have a demonstrated track record of pediatric cancer research with experience in translational research.
- Multiple investigator applications that bring together pairs or teams of researchers with complementary expertise are encouraged.
|
|
Cancer Center Summer Training for Medical Students
Deadline: Mar 31, 2017
There are 9 openings available, with 5 supported by the Brian Werbel Memorial Fund and 4 by the Case Comprehensive Cancer Center.
Details:
- Completed application and reference letter due by: Friday, March 31, 2017
- Awardees must be conducting cancer research with a Case Comprehensive Cancer Center member. View list of members.
- Those receiving the Brian Werbel Memorial Fund awards must attend the annual golf outing.
|
| Case CCC Funding for Pilot/Phase I Clinical Trials
Deadline: Rolling
The Case CCC is encouraging investigators to submit Letters of Intent (LOI) for
Early Phase Clinical Research Support (EPCRS) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Priority will be given to trials which are developed jointly between UH and CCF with planned accrual at both institutions.
The proposals are being accepted on a rolling basis subject to availability of funds.
Please direct any questions and/or submit LOIs to Katarzyna Karelus, Case CCC Clinical Research Office,
[email protected], 216.844.4176.
|
NIH BULLETIN- Notices and Funding Opportunities
|
Cancer Moonshot
The National Cancer Institute (NCI) Cancer Moonshot Implementation Team for Fusion Oncoproteins in Childhood Cancers is seeking broad input and feedback from sources of expertise and interest in these oncogenic drivers of childhood cancers. This input is requested so that the Implementation Team can develop potential state-of-the-science funding opportunities to accelerate progress in developing therapeutic strategies for successfully targeting these oncogenic proteins.
|
for Applications/Program Announcements
Supplements for Validating the Use of Automated Sources of Residential Histories in Cancer Epidemiology Cohorts (Admin Supp)(PA-17-222)
Deadline: Jun 1, 2017
Supplement Opportunity to Support Population-Based Research Studies of Rare Cancers (Admin Supp)(PA-17-223)
Deadline: Jun 1, 2017
Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies (Admin Supp)(PA-17-224)
Deadline: Jun 1, 2017
Revision Applications to NCI-supported R01 Awards to Include Research on the NCI's Provocative Questions (R01)(RFA-CA-17-019)
Deadline: Jun 28, 2017; Oct 30, 2017; Jun 28, 2018; Oct 30, 2018
Revision Applications to National Cancer Institute (NCI)-supported U01 Awards to Include Research on the NCI's Provocative Questions (U01)(RFA-CA-17-020)
Deadline: Jun 28, 2017; Oct 30, 2017; Jun 28, 2018; Oct 30, 2018
Revision Applications to National Cancer Institute (NCI)-supported P01 Awards to Include Research on the NCI's Provocative Questions (P01)(RFA-CA-17-021)
Deadline: Jun 28, 2017; Oct 30, 2017; Jun 28, 2018; Oct 30, 2018
Revision Applications to National Cancer Institute (NCI)-supported P50 Awards to Include Research on the NCI's Provocative Questions (P50)(RFA-CA-17-022)
Deadline: Jun 28, 2017; Oct 30, 2017; Jun 28, 2018; Oct 30, 2018
Center for Coordination of Analytics, Science, Enhancement , and Logistics (CASEL) in Tobacco Regulatory Science (U54)(RFA-OD-17-002)
Deadline: Jul 19, 2017
Informative Webinar: Mar 27 11a-12:30p
Mechanisms of Alcohol-associated Cancers (R01)(PA-17-220)
Deadline: Jun 16, 2017 (new); Jul 16, 2017 (renewal/resubmission); Sep 7, 2017 (AIDS/AIDS-related); Oct 16, 2017 (new)
Mechanisms of Alcohol-associated Cancers (R21)(PA-17-219)
Deadline: Jun 16, 2017 (new); Jul 16, 2017 (renewal/resubmission); Sep 7, 2017 (AIDS/AIDS-related); Oct 16, 2017 (new)
Revision Applications to NCI-supported R01 Awards to Include Research on the NCI's Provocative Questions (R01)(RFA-CA-17-019)
Deadline: Jun 28; Oct 30; Jan 28, 2018; Oct 30, 2018
Revision Applications to National Cancer Institute (NCI)-Supported U01 Awards to Include Research on the NCI's Provocative Questions (U01)(RFA-CA-17-020)
Deadline: Jun 28; Oct 30; Jan 28, 2018; Oct 30, 2018
Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)(PAR-15-075)
Deadline: May 7, 2017 (AIDS/AIDS-related); Jun 5, 2017 (new); Jul 5, 2017 (renewal/resubmission); Sep 7, 2017 (AIDS/AIDS-related) |
|
Applicant Information Webinar to be held March 27, 2017 from 3-4:30p EST
Applicant Information Webinar to be held March 27, 2017 from 11a-12:20p EST
|
|
|
FOLLOW US
|
News from NCI
Mark your Calendars
In the News
Funding Opportunities
NIH Cancer Bulletin
|
VELOSANO 2017
Jul 21-23, 2017
Ride with Us!
Monthly Meet & Greet Happy Hours
Support Team Case CCC
Join us for monthly happy hours at TOLI (
Tavern of Little Italy) on the 2nd Thursday of every month. Kicks off Apr 13 at 4:30p
|
EVENTS
|
|
Wed, Mar 22
Hematology and Oncology Fellows
8a Lerner B-151
|
|
Thurs, Mar 23
Developmental Therapeutics Journal Club
9a R4-013
Dermatology Grand Rounds
Edward Maytin MD, PhD
Assistant Professor, Dermatology, Biomedical Engineering, CWRU/Cleveland Clinic
Member, Case Comprehensive Cancer Center
9:30a BRB 105
|
|
Fri, Mar 24
Cancer Center Seminar Series
12p BRB 105
|
|
Mon, Mar 27
Cancer Center Research Chalk Talk
1p WRB 3-136
|
|
Tues, Mar 28
THOR Seminar
Candece Gladson, MD
Professor, Cancer Biology, Lerner Research Institute, Cleveland Clinic
Member, Case Comprehensive Cancer Center
1p R3-027
Cancer Biology Invited Guest Speaker
Yang Liu, PhD
Children's National Medical Center
"CTLA-4 in cancer immunotherapy, challenges and opportunities"
2p NC1-202
Cancer Center Research in Progress Seminar
David Danielpour, PhD
Professor, Div. of General Medical Sciences-Oncology and Pharmacology, CWRU
Member, Case Comprehensive Cancer Center
"Exploring Novel Therapeutic Targets for Prostate Cancer"
3p WRB 3-136
|
|
Wed, Mar 29
Hem/Onc Div Res Conf
8a Lerner B-151
Frontiers in Biological Sciences Lecture Series
Peter Walter, PhD
Investigator, Howard Hughes Medical Institute
Distinguished Professor, Biochemistry & Biophysics,
University of California San Francisco
"The Unfolded Protein Response and Beyond"
4p E501
Genomic Medicine Institute
Peter Nagy, PhD
Genomic Medicine Institute, Cleveland Clinic
"Analysis of NGS data - constitutional and cancer-related"
5p Q1-300
|
|
Thurs, Mar 30
Developmental Therapeutics Journal Club
9a R4-013
|
|
Fri, Mar 31
Cancer Center Seminar Series
Stephen J. Lippard, PhD
Arthur Amos Noyes Professor of Chemistry, Massachusetts Institute of Technology
"Platinum and Other Metal-Based Anticancer Drugs"
12p BRB 105
|
ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™
Mar 23-25, 2017
Rosen Shingle Creek
Orlando, FL
CWRU/ACS Colleges Against Cancer -Cancer Research Fair
4-6p Hovorka Auditorium, CWRU Campus
AACR Annual Meeting 2017
Apr 1-5, 2017
Walter E. Washington Convention Center
Washington, DC
Advances in the Multidisciplinary Management of Lung Cancer: From Screening to Immunotherapy
Apr 22, 2017 InterContinental Hotel
Hyaluronan Cleveland 2017
Jun 11-15, 2017
InterContinental Hotel
International Cancer Education Conference
Sep 13-15, 2017
Westin Cleveland Downtown
GvHD National Symposium
Oct 13, 2017
Grand Event Center, Columbus, OH
|
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Deadline: Open
Deadline: Open
Deadline: Open
|
|
 |
|
